Literature DB >> 11839555

Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice.

Jingsong Zhao1, Wei Shi, Yan-Ling Wang, Hui Chen, Pablo Bringas, Michael B Datto, Joshua P Frederick, Xiao-Fan Wang, David Warburton.   

Abstract

Transforming growth factor-beta (TGF-beta) signaling plays an important regulatory role during lung fibrogenesis. Smad3 was identified in the pathway for transducing TGF-beta signals from the cell membrane to the nucleus. Using mice without Smad3 gene expression, we investigated whether Smad3 could regulate bleomycin-induced pulmonary fibrosis in vivo. Mice deficient in Smad3 demonstrated suppressed type I procollagen mRNA expression and reduced hydroxyproline content in the lungs compared with wild-type mice treated with bleomycin. Furthermore, loss of Smad3 greatly attenuated morphological fibrotic responses to bleomycin in the mouse lungs, suggesting that Smad3 is implicated in the pathogenesis of pulmonary fibrosis. These results show that Smad3 contributes to bleomycin-induced lung injury and that Smad3 may serve as a novel target for potential therapeutic treatment of lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839555     DOI: 10.1152/ajplung.00151.2001

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  149 in total

Review 1.  Lung organogenesis.

Authors:  David Warburton; Ahmed El-Hashash; Gianni Carraro; Caterina Tiozzo; Frederic Sala; Orquidea Rogers; Stijn De Langhe; Paul J Kemp; Daniela Riccardi; John Torday; Saverio Bellusci; Wei Shi; Sharon R Lubkin; Edwin Jesudason
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

2.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

Review 3.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

4.  Receptor-activated Smad localisation in bleomycin-induced pulmonary fibrosis.

Authors:  Hiroyuki Higashiyama; Daisuke Yoshimoto; Yuji Okamoto; Hideo Kikkawa; Satoshi Asano; Mine Kinoshita
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

5.  Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice.

Authors:  Huimin Zhang; William E Lawson; Vasiliy V Polosukhin; Ambra Pozzi; Timothy S Blackwell; Ying Litingtung; Chin Chiang
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.

Authors:  Hongmei Gu; Amanda J Fisher; Elizabeth A Mickler; Frank Duerson; Oscar W Cummings; Marc Peters-Golden; Homer L Twigg; Trent M Woodruff; David S Wilkes; Ragini Vittal
Journal:  FASEB J       Date:  2016-03-08       Impact factor: 5.191

7.  Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis.

Authors:  Meredith L Sosulski; Rafael Gongora; Carol Feghali-Bostwick; Joseph A Lasky; Cecilia G Sanchez
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-05-01       Impact factor: 6.053

8.  Neonatal hyperoxia increases sensitivity of adult mice to bleomycin-induced lung fibrosis.

Authors:  Min Yee; Bradley W Buczynski; B Paige Lawrence; Michael A O'Reilly
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-20       Impact factor: 6.914

9.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14

10.  Inhibition of transforming growth factor-beta signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice.

Authors:  S Segawa; D Goto; Y Yoshiga; M Sugihara; T Hayashi; Y Chino; I Matsumoto; S Ito; T Sumida
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.